- \n
- The\u00a0\u2018Ms. Represented\u2019<\/em> campaign expands its reach with professional snowboarder Chloe Kim, who shares her ADHD experience to help connect with a younger generation of women.<\/li>\n
- More than 60% of U.S. women who reported ever receiving an ADHD diagnosis were first diagnosed in adulthood, underscoring the importance of recognizing experiences that don’t fit familiar perceptions of the condition.1<\/sup><\/li>\n
- Chloe is partnering with Qelbree, the #1 prescribed branded non-stimulant ADHD medication as of May 2026 which has reached approximately 3 million prescriptions filled since launch in 2021.*<\/li>\n<\/ul>\n
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) — Professional snowboarder Chloe Kim is bringing her personal attention-deficit\/hyperactivity disorder (ADHD) journey to \u2018Ms. Represented,\u2019<\/em> a campaign from Supernus Pharmaceuticals for Qelbree (viloxazine extended-release capsules), a once-a-day, non-stimulant ADHD treatment for people ages 6 years and older. Diagnosed with ADHD as an adult, Chloe didn\u2019t recognize her own experience in familiar portrayals of ADHD. Now, as a paid spokesperson for Supernus, she is opening up about her journey to change the conversation and help other women feel seen, understood, and represented.<\/p>\n
Launched last year, the \u2018Ms. Represented\u2019<\/em> campaign challenges the narrow perceptions of ADHD that can leave women feeling misrepresented. Boys are nearly twice as likely as girls to be diagnosed with ADHD, while the percentage of women ages 23\u201349 newly diagnosed with the condition nearly doubled between 2020 and 2022.2<\/sup>,<\/sup>3<\/sup> While ADHD is often associated with hyperactivity and impulsivity, it can also involve inattentive symptoms, including less visible experiences such as getting easily distracted or having difficulty with organization.4<\/sup> For Chloe, recognizing patterns in her own experiences helped her better understand her ADHD diagnosis, bringing another perspective to the campaign and helping connect with a younger generation of women.<\/p>\n
\u201cWhen I was diagnosed with ADHD, so much about what I had been experiencing finally made sense,\u201d said Chloe. \u201cI hope that by sharing my story, more women feel empowered to ask questions, seek support, and know that having ADHD doesn\u2019t limit what they\u2019re capable of achieving.\u201d<\/p>\n
Following Chloe\u2019s diagnosis, she explored treatment options with her doctor and now takes once-a-day, non-stimulant Qelbree to help manage her ADHD symptoms. Initially approved for children ages 6-17 years in April 2021 and subsequently for adults in April 2022, Qelbree offers a treatment option for the nearly 16 million adults and 7 million adolescents living with ADHD in the U.S.5<\/sup>,<\/sup>6<\/sup><\/p>\n
\u201cThrough the \u2018Ms. Represented\u2019<\/em> campaign, we’re continuing to challenge the misconceptions that have left women’s experiences with ADHD overlooked for too long,\u201d said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. \u201cChloe brings an important perspective to that mission, and as we mark five years of Qelbree, we remain committed to raising awareness and providing a non-stimulant treatment option to help people manage their ADHD symptoms.\u201d<\/p>\n
Designed to inspire action, the\u00a0\u2018Ms. Represented\u2019<\/em>\u00a0campaign meets women where they are, using engaging storytelling to spark vital health conversations. By connecting the dots across her passions, from snowboarding, fashion to mental health, Chloe brings the initiative to life in editorial collaborations with\u00a0Coveteur<\/em>\u00a0and\u00a0PureWow<\/em>, alongside an appearance on\u00a0a social-first episode of Are You Okay?<\/em>.<\/p>\n
To learn more about Chloe’s story and the \u2018Ms. Represented<\/em>\u2019 campaign, visit www.qelbree.com\/msrepresented<\/a>. For more information about Qelbree, visit www.qelbree.com<\/a>.<\/p>\n
*Qelbree\u2019s pediatric indication was approved for children ages 6-17 years in April 2021.<\/p>\n
INDICATION<\/strong><\/p>\n
Qelbree\u00ae<\/sup> (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children 6 years and older.<\/p>\n
IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child\u2019s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.<\/strong><\/p>\n
You or your child should not take Qelbree if you or your child:<\/strong>
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.<\/p>\nQelbree can increase blood pressure and heart rate.<\/strong> Your or your child\u2019s doctor will monitor these vital signs.<\/p>\n
Qelbree may cause manic episodes in patients with bipolar disorder. <\/strong>Tell your doctor if you or your child show any signs of mania.<\/p>\n
Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child.<\/strong> Qelbree may cause you or your child to feel sleepy or tired.<\/p>\n
The most common side effects of Qelbree<\/strong> in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.<\/p>\n
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov\/medwatch<\/a> or call 1-800-FDA-1088.<\/p>\n
Please see full Prescribing Information, including Boxed Warning, and Medication Guide <\/strong>here<\/strong><\/a>.<\/strong><\/p>\n
Qelbree (viloxazine extended-release capsules) is available in 100 mg, 150 mg and 200 mg capsules.<\/p>\n
About Supernus Pharmaceuticals, Inc.<\/strong>
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.<\/p>\nOur diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson\u2019s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.<\/p>\n
For more information, please visit www.supernus.com<\/a>.<\/p>\n
Qelbree is a registered trademark of Supernus Pharmaceuticals, Inc.
\u00a92026\u00a0Supernus Pharmaceuticals, Inc. All rights reserved.<\/p>\n- \n
- Centers for Disease Control and Prevention (CDC). National Center for Health Statistics Rapid Surveys System, Round 2: ADHD. October\u2013November 2023. https:\/\/www.cdc.gov\/nchs\/rss\/round2\/adhd.html<\/a> \u00a0\u00a0<\/li>\n
- Reuben C., Elgaddal N. (2024) Attention-deficit\/hyperactivity disorder in children ages 5\u201317 years: United States, 2020\u20132022. NCHS Data Brief, no 499. Hyattsville, MD: National Center for Health Statistics.<\/li>\n
- Russell, J., et al. (2023). Number of ADHD Patients Rising, Especially Among Women. Epic Research.<\/li>\n
- Quinn, P.O. and Madhoo, M. (2014). A Review of Attention Deficit\/Hyperactivity Disorder in Women and Girls: Uncovering This Hidden Diagnosis. Prim Care Companion CNS Disord.<\/li>\n
- Centers for Disease Control and Prevention (CDC). ADHD in Adults: An Overview. October 8, 2024. https:\/\/www.cdc.gov\/adhd\/articles\/adhd-across-the-lifetime.html<\/a><\/li>\n
- CDC. Data and Statistics on ADHD. November 19, 2024. https:\/\/www.cdc.gov\/adhd\/data\/index.html<\/a><\/li>\n<\/ol>\n
CONTACTS: <\/strong><\/p>\n
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591<\/p>\nOr<\/p>\n
INVESTOR CONTACT: <\/strong>
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com<\/a><\/p>\nOr<\/p>\n
- More than 60% of U.S. women who reported ever receiving an ADHD diagnosis were first diagnosed in adulthood, underscoring the importance of recognizing experiences that don’t fit familiar perceptions of the condition.1<\/sup><\/li>\n